Lenalidomida Stada

Lenalidomide, the active ingredient in Lenalidomida Stada, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in appropriate patients.

GNH USA supplies Lenalidomida Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies that respond to immunomodulatory therapy.

Multiple Myeloma: improves progression‑free survival and overall response rates when combined with dexamethasone or proteasome inhibitors. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and cytopenias. Mantle Cell Lymphoma: enhances response when added to standard chemo‑immunotherapy regimens.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count, increasing infection risk. - Thrombocytopenia: low platelet levels, may cause bleeding. - Fatigue: persistent tiredness. - Nausea: upset stomach and vomiting. - Diarrhea: loose stools. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic failure: liver dysfunction with jaundice.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

Pregnancy: contraindicated; ensure effective contraception. Renal impairment: assess renal function and adjust dose if needed. Thromboembolic risk: consider prophylactic anticoagulation in high‑risk patients. Hematologic monitoring: perform regular CBC to detect cytopenias. Drug interactions: review concomitant medications for potential CYP3A4 effects. Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Lenalidomide can interact with several agents, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened infection risk due to immunosuppression. - Teratogenic agents: combined exposure contraindicated in pregnancy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase drug levels. - NSAIDs: potential additive renal toxicity. - Antihistamines: may enhance sedation or dizziness.